Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, Latiff G, Pokrovsky V, Bredeek F, Smith G, Cahn P, Kim YS, Ford SL, Talarico CL, Patel P, Chounta V, Crauwels H, Parys W, Vanveggel S, Mrus J, Huang J, Harrington CM, Hudson KJ, Margolis DA, Smith KY, Williams PE, Spreen WR. Swindells S, et al. Among authors: smith g, smith ky. N Engl J Med. 2020 Mar 19;382(12):1112-1123. doi: 10.1056/NEJMoa1904398. Epub 2020 Mar 4. N Engl J Med. 2020. PMID: 32130809 Clinical Trial.
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA, Brinson CC, Smith GHR, de Vente J, Hagins DP, Eron JJ, Griffith SK, Clair MHS, Stevens MC, Williams PE, Ford SL, Stancil BS, Bomar MM, Hudson KJ, Smith KY, Spreen WR; LAI116482 Study Team. Margolis DA, et al. Lancet Infect Dis. 2015 Oct;15(10):1145-1155. doi: 10.1016/S1473-3099(15)00152-8. Epub 2015 Jul 19. Lancet Infect Dis. 2015. PMID: 26201299 Clinical Trial.
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
Smith GHR, Henry WK, Podzamczer D, Masiá MDM, Bettacchi CJ, Arasteh K, Jaeger H, Khuong-Josses MA, Montes-Ramírez ML, Stellbrink HJ, Yazdanpanah Y, Richmond GJ, Sutton KC, Zhang F, McCoig CC, St Clair MH, Vandermeulen K, Van Solingen-Ristea R, Smith KY, Margolis DA, Spreen WR. Smith GHR, et al. Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. doi: 10.1093/ofid/ofab439. eCollection 2021 Sep. Open Forum Infect Dis. 2021. PMID: 34557563 Free PMC article.
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study.
Sutton KC, De Vente J, Leblanc R, Dejesus E, Smith G, Mills A, Baril JG, St Clair M, Stancil BS, Vandermeulen K, Spreen WR. Sutton KC, et al. Among authors: smith g. Open Forum Infect Dis. 2022 Feb 9;9(4):ofac067. doi: 10.1093/ofid/ofac067. eCollection 2022 Apr. Open Forum Infect Dis. 2022. PMID: 35350172 Free PMC article.
Cardiovascular Events in an Inner-City HIV Clinic and Relationship to Abacavir Versus Tenofovir Disoproxil Fumarate-Containing Antiretroviral Regimens.
Varriano B, Crouzat F, Sandler I, Smith G, Kovacs C, Gupta M, Brunetta J, Fletcher D, Knox D, Merkley B, Chang B, Tilley D, Acsai M, Loutfy M. Varriano B, et al. Among authors: smith g. AIDS Res Hum Retroviruses. 2021 Jan;37(1):44-53. doi: 10.1089/AID.2020.0053. Epub 2020 Nov 2. AIDS Res Hum Retroviruses. 2021. PMID: 33019803
Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.
Antoniou T, Raboud JM, Diong C, Su D, Dewhurst N, Buckley V, Kovacs C, Rachlis A, Brunetta J, Smith G, Gough K, Fletcher D, Loutfy MR. Antoniou T, et al. Among authors: smith g. J Int Assoc Physicians AIDS Care (Chic). 2010 Nov-Dec;9(6):382-9. doi: 10.1177/1545109710382041. J Int Assoc Physicians AIDS Care (Chic). 2010. PMID: 21138833
Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-).
Antoniou T, Smith G, Su D, Raboud JM, Lee D, Kovacs C, Brunetta J, Fletcher D, Crouzat F, Loutfy M. Antoniou T, et al. Among authors: smith g. J Int Assoc Physicians AIDS Care (Chic). 2012 May-Jun;11(3):192-7. doi: 10.1177/1545109711424967. Epub 2012 Jan 13. J Int Assoc Physicians AIDS Care (Chic). 2012. PMID: 22247337
15,251 results
You have reached the last available page of results. Please see the User Guide for more information.